Reverb Therapeutics
David de Graaf is an accomplished biotechnology executive with extensive experience in leadership roles, currently serving as Co-Founder, CEO, and President of Reverb Therapeutics since September 2022, where the focus is on bispecific antibodies for modulating cytokine signaling. Additionally, David co-founded NewCo in February 2024 and holds the position of Board Chair, while also serving as Executive Chair at Ability Biologics and Managing Partner at Inkling LLC. Prior roles include President & CEO at Abcuro, Inc., where innovative treatments for autoimmune and cancer indications were developed, and CEO at Syntimmune, which specialized in autoimmune diseases. David's academic credentials include a PhD in Mammalian Genetics from the University of Illinois Chicago and a postdoctoral degree in Genomics from the Weizmann Institute of Science, complemented by a MSc in Evolutionary Genetics from Utrecht University.
This person is not in any teams
This person is not in any offices
Reverb Therapeutics
We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.